Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 Lymphoma Highlights
25 June 2024 | Virtual Meeting
Presentation summaries of key lymphoma abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts
The Post-ASCO & EHA 2024 Lymphoma highlights was supported by AstraZeneca and Genentech. Supporters have no influence over the production of content.
Updates in mantle cell and follicular lymphomas
Glofitamab monotherapy for heavily pretreated R/R MCL
Tycel Phillips City of Hope, Duarte, CA, United States
EPCORE NHL‑1: Epcoritamab induces deep responses in R/R FL
Umberto Vitolo Candiolo Cancer Institute, Turin, Italy
Session 1 panel discussion
Updates in B-cell lymphomas
Golcadomide + R-CHOP in pts with untreated A-BCL
Marc Hoffmann University of Kansas Cancer Center, Kansas City, KS, United States
Outcomes with axicabtagene ciloleucel for R/R PMBCL from the DESCAR-T registry
Jean Galtier University Hospital of Bordeaux, Bordeaux, France
RW assessment of anti-CD19 CAR-T in pts aged ≥75 w. R/R LBCL from the DESCAR-T registry
Pierre Bories Toulouse University Institute of Cancer, Toulouse, France
Session 2 panel discussion
Updates in Hodgkin and non-Hodgkin lymphomas
EORTC-1537-COBRA: FDG-PET-response adapted targeted therapy for adv. HL
Martin Hutchings Copenhagen University Hospital, Copenhagen, Denmark
HD16 & HD18: Serum TARC + FDG-PET imaging for classic HL
Wouter Plattel University Medical Center Groningen, Groningen, Netherlands
Session 3 panel discussion
Updates in T-cell lymphomas
VALENTINE-PTCL01: Valemetostat in pts with R/R PTCL
Steven Horwitz Memorial Sloan Kettering Cancer Center, New York City, NY, United States
International Perspective T-cell Project 2.0: baseline PET total MTV in PTCLS
Tetiana Skrypets Giovanni Paolo II / I.R.C.C.S. Cancer Institute, Bari, Italy
HUCART19-IL18 in R/R lymphomas following progression on anti-CD19 CAR T-cell therapy
Jakub Svoboda Abramson Cancer Center, Philadelphia, PA, United States
Auto- and allo-SCT for T-cell lymphoma
Evgenii Shumilov Münster University Hospital, Münster, Germany
Session 4 panel discussion
Supported by:
Diamond Supporters
Gold Supporters
